INS and Hypoglycemia: Although several pharmacological options exist, including insulin secretagogues, insulin sensitizers, and glucose absorption inhibitors [7,8], current therapies often fail to achieve long-term glycaemic control and are associated with adverse effects such as hypoglycaemia, weight gain, gastrointestinal discomfort, and increased cardiovascular risk [9–14].